No Data
No Data
US FDA Approves King-Friend Biochemical Pharma's Abbreviated New Drug Application for Cancer Drug
nanjing king-friend biochemical pharmaceutical (603707.SH): Subsidiary product fluorouracil injection approved by the FDA in the usa.
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced on September 25 that its subsidiary, Jianjin Pharmaceuticals Co., Ltd. (referred to as "Jianjin Pharmaceuticals"), recently received approval notification for the fluorouracil injection, 2.5g/50mL (50mg/mL) pharmacy bulk package ANDA issued by the Food and Drug Administration (referred to as "FDA") of the United States. Indications: Used for the treatment of breast and digestive system (colon, rectal, stomach, pancreas) gland cancer.
Is Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Using Too Much Debt?
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH): Oxaliplatin Injection Obtains Pharmaceutical Registration Certificate.
Nanjing King-Friend Biochemical Pharmaceutical (603707.SH) announced that its subsidiary, Jiangsu Jindel Pharmaceutical Co., Ltd., recently received a notice from the National Medical Products Administration approving and issuing a registration certificate for Osimertinib injections (specifications: 10ml: 50mg and 20ml: 100mg). The subsidiary's Osimertinib injections have obtained the drug registration certificate from the National Medical Products Administration, indicating that the company has the qualification to sell the pharmaceutical in the domestic market. This further enriches the company's product line and helps improve its market competitiveness. According to relevant national policies, Jiangsu Jindel Pharmaceutical's Osimertinib injections
Jianyou Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Jianyou Co., Ltd.
No Data
No Data